Bellevue Life Sciences Acquisition Corp. Stock

Equities

BLAC

US0791741087

Investment Holding Companies

Delayed Nasdaq 12:52:24 2024-05-09 pm EDT 5-day change 1st Jan Change
10.8 USD -0.18% Intraday chart for Bellevue Life Sciences Acquisition Corp. +0.84% +2.86%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2022 - Sales 2023 - Capitalization 95.08M
Net income 2022 - Net income 2023 - EV / Sales 2022 * -
Net Debt 2022 1.09M Net Debt 2023 56.58K EV / Sales 2023 -
P/E ratio 2022 *
-
P/E ratio 2023
210 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 62.64%
More Fundamentals * Assessed data
Dynamic Chart
Bellevue Life Sciences Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Bellevue Life Sciences Acquisition Corp. announced that it has received $0.05 million in funding CI
Bellevue Life Sciences Acquisition Corp. announced that it has received $1.2 million in funding CI
Bellevue Life Sciences Acquisition Corp. announced that it has received $0.06 million in funding CI
Bellevue Life Sciences Acquisition Corp. announced that it has received $0.075 million in funding CI
Bellevue Life Sciences Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Bellevue Life Sciences Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Certain Common Stock of Bellevue Life Sciences Acquisition Corp. are subject to a Lock-Up Agreement Ending on 9-AUG-2023. CI
Bellevue Life Sciences Acquisition Plans to Take OSR Holdings Public in SPAC Merger Deal MT
Bellevue Life Sciences Acquisition Corp. entered into an exclusive, non-binding letter of intent to acquire OSR Holdings, Ltd. CI
Bellevue Life Sciences Acquisition Corp. announced that it has received $0.2 million in funding CI
Bellevue Life Sciences Acquisition Corp. Announces the Resignation of Hosun Euh as Member of the Board of Directors, Effective June 21, 2023 CI
Bellevue Life Sciences Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Bellevue Life Sciences Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Bellevue Life Sciences Acquisition Corp. Auditor Raises 'Going Concern' Doubt CI
More news
1 day-0.09%
1 week+0.84%
Current month+0.65%
1 month+0.93%
3 months+2.27%
6 months+3.55%
Current year+2.86%
More quotes
1 week
10.71
Extreme 10.71
11.60
1 month
10.64
Extreme 10.64
11.60
Current year
10.50
Extreme 10.5
11.60
1 year
10.15
Extreme 10.15
11.60
3 years
10.07
Extreme 10.07
11.60
5 years
10.07
Extreme 10.07
11.60
10 years
10.07
Extreme 10.07
11.60
More quotes
Managers TitleAgeSince
Chief Executive Officer 48 20-02-29
Director of Finance/CFO 50 21-08-31
Members of the board TitleAgeSince
Chairman 73 23-02-13
Director/Board Member 60 23-02-13
Chief Executive Officer 48 20-02-29
More insiders
Date Price Change Volume
24-05-09 10.8 -0.18% 746
24-05-08 10.82 +1.01% 3,621
24-05-07 10.71 -0.07% 1,068
24-05-06 10.72 +0.09% 24,991
24-05-03 10.71 -0.00% 18,101

Delayed Quote Nasdaq, May 09, 2024 at 12:52 pm EDT

More quotes
Bellevue Life Sciences Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The Company has not selected any business combination target, and has not engaged in any substantive discussions, directly or indirectly, with any business combination target. The Company may pursue an acquisition opportunity in any business industry or sector. The Company intends to acquire and manage a business in the healthcare industry, more specifically in the biotechnology sector. The Company neither engaged in any operations nor generated any revenues.
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW